Spark Therapeutics
ONCE
ONCE was delisted on the 16th of December, 2019.
127 hedge funds and large institutions have $1.71B invested in Spark Therapeutics in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 37 reducing their positions, and 10 closing their positions.
129% more call options, than puts
Call options by funds: $8.66M | Put options by funds: $3.78M
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
64% more capital inflows, than outflows
Capital inflows: $180M | Capital outflows: $110M
41% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 37
4% more funds holding
Funds holding: 122 → 127 (+5)
2.24% more ownership
Funds ownership: 89.68% → 91.92% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$44M |
| 2 |
Janus Henderson Group
London,
|
+$28.9M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$17.3M |
| 4 |
BlackRock
New York
|
+$11.9M |
| 5 |
IPLA
Ice Pond Lane Advisers
New York
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$25M |
| 2 |
Deerfield Management
New York
|
-$15.1M |
| 3 |
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$12.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.2M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$9.22M |
ONCE Hedge Fund Activity: Q2 2017 in Review
127 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics (ONCE) for Q2 2017, worth a combined $1.71B — up 15% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ONCE positions and 10 closed out — a net gain of 7 holders — while 52 added to existing stakes and 37 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $44M. The largest seller was American Century Companies, cutting an estimated $25M.
- 127 institutional investors held Spark Therapeutics (ONCE) as of Q2 2017, up from 122 in Q1 2017.
- Funds reported $1.71B of Spark Therapeutics stock for Q2 2017, up 15% quarter-over-quarter.
- 17 funds opened new Spark Therapeutics positions in Q2 2017 and 10 closed out, a net change of +7 holders.
- The largest Spark Therapeutics buyer in Q2 2017 was Citadel Advisors, an estimated $44M added.
- The largest Spark Therapeutics seller in Q2 2017 was American Century Companies, an estimated $25M sold.
Based on aggregated 13F filings for Q2 2017.